FR-167356_product_DataBase

Bioactivity	FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss[1].
In Vivo	FR-167356 (200 mg/kg; 口服; 每天, 持续 10 天; 具有 B16-F10 异种移植物的雄性 C57BL/6 小鼠) 抑制肿瘤生长并降低 MMP9 表达[1]。FR-167356 (200 mg/kg; 口服; 每天, 持续 10 天; 具有 B16-F10 异种移植物的雄性 C57BL/6 小鼠) 与未治疗组相比减少骨转移[1]。 Animal Model:
Name	FR-167356
CAS	174185-16-1
Formula	C19H17Cl2NO3
Molar Mass	378.25
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Nishisho T, et, al. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55. [2]. Niikura K, et, al. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88.

PeptideDB